Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

962
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
962
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

887
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
887
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collaboratively Designing an App for a More Personalized, Community-Endorsed Continuous Glucose Monitoring Onboarding Experience: An Early Study.

Journal of diabetes science and technology·2023
Same author

Zooming In, Then Out: Why We Must Apply Human-Centered Design to Transform Diabetes Technology.

Journal of diabetes science and technology·2023
Same author

A smoothed corrected score approach for proportional hazards model with misclassified discretized covariates induced by error-contaminated continuous time-dependent exposure.

Biometrics·2021
Same author

Simulation Extrapolation Method for Cox Regression Model with a Mixture of Berkson and Classical Errors in the Covariates using Calibration Data.

The international journal of biostatistics·2019
Same author

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.

Core evidence·2012
Same author

Dapagliflozin--redefining treatment of T2DM?

Nature reviews. Endocrinology·2011

Related Experiment Video

Updated: Apr 5, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Edward C Chao

    Clinical Diabetes : a Publication of the American Diabetes Association
    |August 7, 2015
    PubMed
    Summary

    Blocking renal sodium-glucose cotransporter 2 (SGLT-2) induces glucose excretion, correcting hyperglycemia independently of insulin. This discovery led to the development of SGLT-2 inhibitors, a new class of diabetes agents.

    Area of Science:

    • Nephrology
    • Endocrinology
    • Pharmacology

    Background:

    • Glucosuria (glucose in urine) traditionally linked to uncontrolled diabetes.
    • Renal sodium-glucose cotransporter 2 (SGLT-2) plays a key role in glucose reabsorption.
    • Understanding SGLT-2 function revealed a novel mechanism for glucose regulation.

    Purpose of the Study:

    • To provide an overview of the paradigm shift in understanding glucosuria.
    • To discuss the development of SGLT-2 inhibitors.
    • To summarize clinical evidence for SGLT-2 inhibitors.

    Main Methods:

    • Review of existing literature on SGLT-2 function and inhibition.
    • Analysis of clinical trial data for SGLT-2 inhibitor efficacy and safety.
    • Synthesis of evidence regarding the mechanism of action.

    More Related Videos

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
    07:00

    Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

    Published on: February 26, 2019

    10.1K

    Related Experiment Videos

    Last Updated: Apr 5, 2026

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
    07:00

    Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

    Published on: February 26, 2019

    10.1K

    Main Results:

    • SGLT-2 inhibition effectively reduces blood glucose by increasing urinary glucose excretion.
    • This mechanism lowers hyperglycemia independently of insulin secretion or sensitivity.
    • Clinical studies demonstrate significant benefits in glycemic control and cardiovascular outcomes.

    Conclusions:

    • The development of SGLT-2 inhibitors represents a major advancement in diabetes treatment.
    • Targeting renal glucose reabsorption offers a novel therapeutic strategy.
    • SGLT-2 inhibitors provide an insulin-independent approach to managing hyperglycemia.